New combo therapy aims to restore gout treatment in non-responders
NCT ID NCT06186219
First seen Nov 20, 2025 · Last updated May 17, 2026 · Updated 30 times
Summary
This early-stage study tested whether giving rituximab before standard methotrexate-pegloticase therapy could help people with severe tophaceous gout who had stopped responding to pegloticase. Only 2 participants were enrolled. The main goal was to check safety and see if the treatment could lower uric acid levels. This is not a cure, as ongoing management is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TOPHACEOUS GOUT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
UCLA
Los Angeles, California, 90095, United States
Conditions
Explore the condition pages connected to this study.